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
The complexity of eukaryotic cells is underscored by the compartmentalisation of 
chemical signals by phospholipid membranes. A grand challenge of synthetic biology 
is building life from the ‘bottom2up’, for the purpose of generating systems simple 
enough to precisely interrogate biological pathways or for adapting biology to 
perform entirely novel functions. Achieving compartmentalisation of chemistries in an 
addressable manner is a task exquisitely refined by Nature and embodied in a 
unique membrane remodelling machinery that pushes membranes away from the 
cytosol, the ESCRT2III complex. Here we show efforts to engineer a single ESCRT2
III protein merging functional features from its different components. The activity of 
such a designed ESCRT2III is shown by its ability to drive the formation of 
compartments encapsulating fluorescent cargo. It appears that the modular nature of 
ESCRT2III allows its functional repurposing into a minimal machinery that perform 
sophisticated membrane remodelling, therefore enabling its use to create eukaryotic2
like multicompartment architectures. 
 
¶ These authors equally contributed to this work. 
§ Corresponding authors. 
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A major challenge in bottom2up synthetic biology is the engineering of artificial cells 
[123]. Inspired by biological cells, these are compartmentalised architectures 
containing functional chemistries in communication with their external environment 
[4]. Development of artificial cells promises novel, highly adaptive and multifunctional 
chemical systems with wide2ranging potential applications in the chemical [5], 
biotechnological [6] and medical industries [7]; as well as contributing to our 
developing rudimentary understanding of these fundamental units of life [8]. Most 
commonly, compartmentalisation strategies for artificial cells closely mimic the 
natural membrane architectures of their living counterparts with much of the early 
work in the endeavour focused on single membrane2bound compartments, 
comparable to a prokaryotic cell [9]. More recently, however, the spotlight has 
started to shift towards multicompartment systems, analogous with eukaryotic cells, 
with the prospect of increased sophistication and complexity of function [10213]. 
 
In Nature, membrane compartmentalisation is controlled by the action of ordered 
protein assemblies that can bend, push or pull the phospholipid bilayer and 
ultimately bud away vesicles [14]. This provides inspiration for  fabrication of 
multicompartment membrane2based systems by repurposing these natural protein 
complexes  	. We focus our attention on the ESCRT complex (Endosomal 
Sorting Complex Required for Transport) involved in the formation of multivesicular 
bodies (MVB), which have architectural similarity to the systems we wish to 
engineer. In particular, ESCRT2III is strongly implicated in the membrane remodeling 
capabilities of ESCRTs [15]. 
 
ESCRT2III proteins assemble on the cytosolic face of MVB to perform membrane 
remodeling and scission of newly formed intraluminal vesicles (ILVs) (Figure 1) [162
18]. ESCRT2III is evolutionary conserved and its complexity decreases going from 

	 to 	, where there are only three components to the complex [19]. In 
	 	, the complex consists of core subunits namely, Vps20, 
Snf7, Vps24, and Vps2 [20]. The main component Snf7 is able to assemble into 
spiral filaments when in contact with phospholipid membranes (Figure 1A; 
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‘filament’) but in the cytoplasm, all ESCRT2III maintain an autoinhibited conformation 
that keeps them soluble [21]. The Snf7 filament is held into place by short N2terminal 
regions that contain hydrophobic aminoacid sequences capable to insert into the 
membrane [22]. However, it is upstream complexes such as ESCRT2II (Figure 1A; 
‘seed’) that initiate membrane invagination and bind to ‘initiator’ Vps20 nucleating 
ESCRT2III assembly at regions of negative membrane curvature (Figure 1A) [23226]. 
Vps20 is the only ESCRT2III component that appears to be myristoylated  , 
possibly to increase its membrane binding affinity and nucleate complex assembly. 
Upon binding to Vps20, Snf7 is capable of self2oligomerisation into circular filaments 
growing radially, a process that is ‘capped’ by the subunits Vps24 and Vps2 [27] 
(Figure 1A; ‘cap’). Vps2 molecules work as strong binders [28] (Figure 1A; ‘adaptor’) 
for the AAA+ ATPase Vps4 (Figure 1A; ‘motor’). , Vps4 hexamers formed in 
the presence of ATP, use N2terminal microtubule interacting and trafficking (MIT) 
domains to anchor the type I MIT interacting motifs (MIM) of Vps2. MIM motifs are 
also present in Snf7 and Vps20 but have lower affinity for Vps4 (type II MIM) [29,30]. 
ATP hydrolysis induces inter2subunit conformational changes within Vps4, which 
mechanically extracts ESCRT2III components from the assembled filament. To date, 
two possible mechanisms have been proposed for membrane remodelling. In the 
‘purse2string’ model, flat ESCRT2III spirals accumulate elastic energy, which is 
released upon ESCRT2III disassembly by Vps4 and used to deform membranes [31]. 
In the ‘dome’ model, ESCRT2III form cylindrical spirals ending in dome2shaped 
structures, with the spirals’ external surfaces interacting with the membrane. The 
domes are lined with Vps2 and Vps24 molecules, which would drive disassembly of 
the dome by recruiting Vps4 [32,33]. Ultimately, these processes dynamically 
remodel nanoscale ESCRT2III spirals into structures with supposedly incrementally 
smaller size, which restrict the neck of the vesicle performing scission of the 
membrane at this point.  Membrane invagination and bud formation by ESCRT2II 
coupled to bud neck restriction by ESCRT2III and Vps4 action result in ILV formation 
within endosomal organelles   [23,34]. Recycling of ESCRT2III filaments by 
Vps4 makes the complex competent for a second round of membrane remodelling 
and ILV formation [29]. It is possible to reconstitute membrane remodelling [35] and 
ILV formation from Giant Unilamellar Vesicles (GUVs) using purified ESCRT2III and 
ESCRT2II components,  	 [18,36]. Furthermore, Vps4 recycling action on 
ESCRT2III has the potential to afford multiple rounds of ILVs, opening the possibility 
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to exploit these proteins to generate multi2compartment architectures within a larger 
membrane structure, segregating different chemical cargo.  
 
The complexity of the ESCRT system does not make it readily amenable to large 
scale preparation for 	 remodelling of GUVs. Therefore, we set out to create an 
all2in2one ESCRT component capable to perform membrane budding and scission. 
Here we show encouraging data suggesting that a very basic design incorporating 
the key elements for membrane insertion and oligomerisation can indeed remodel 
phospholipid membranes 	. 
 
	

!
		"	
 #	The synthetic gene 
for the Snf72Vps2 chimera (Supplementary data), with the 	
	 N2myristyl transferase (NMT) recognition sequence MGQKSS replacing 
the first 11 residues of Snf7, was synthesised and subcloned by DC Biosciences 
(Dundee, UK) into a modified pET32a with a C2terminal hexa2histidine tag. Plasmids 
containing genes encoding the Vps4 (pGST2Vps4; Addgene plasmid # 21495), 
Snf7(pMBP2HIS22Snf7; Addgene plasmid # 21492), Snf72Vps2 chimera and NMT 
(pNMT; Addgene plasmid # 42578) [37] were transformed into competent JM109 
cells and grown for 16 hours at 25ºC in 2xYT autoinduction media, containing trace 
metals (Formedium). For the chimera to be myristoylated the media was 
supplemented with myristic acid (10 mg/L) and ZnSO4 (0.1 mM).  
 
Cells from 1L of culture were resuspended in 15ml of ice cold PBS (50 mM NaPO4 
pH 7.4, 150 mM NaCl) with EDTA2Free protease inhibitor cocktail (Roche). Cells 
were sonicated on ice for 30” with 30’’ rest on ice and clarified by centrifugation at 
30,000 x g for 30’ at 4ºC. For the Snf72Vps2 chimera, the supernatant was applied to 
Profinity IMAC Ni2charged resin (Biorad) pre2equilibrated in PBS and incubated at 
4oC for one hour with gentle rotation. The resin was washed with at least five column 
volumes of PBS and a final wash of one column volume of PBS with 50 mM 
imidazole. The bound protein was eluted with PBS containing 300 mM imidazole and 
then applied to a pre2equilibrated (PBS) Superdex 75 30/100 GL (GE Healthcare) 
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size2exclusion column. The peak corresponding to the monomeric protein was 
separated into aliquots, flash frozen in liquid nitrogen and stored at 280ºC. 
 
The supernatant from bacterial cells overexpressing the Snf7 protein fused to 
Maltose2Binding2Protein (MPB) was filtered through a 0.45PM membrane and 
applied to 5 x 1 ml MBPTrap HP (GE Healthcare) at a flow rate of 1ml/min. After 7 
column volumes of PBS MBP2Snf7 was eluted with 3 column volumes of PBS 
containing 10 mM maltose. The MBP tag was removed by incubation overnight with 
excess TEV protease and 1 mM DTT. After cleavage, the tag and TEV were 
removed by passing through a Ni2+ column (both TEV and MBP contain a histidine 
tag) monomeric protein was resolved from aggregates using SEC. 
 
 
$% 
			&$'	#	 
Prior to mass spectrometry prot ins were separated on an Agilent 260 Infinity liquid 
chromatography instrument. 1µl of protein sample (in PBS) was injected onto a 
Phenomenex Aeris Widepore column (3.6u, XB2C18, 50mm x 2.2mm) with a flow 
rate of 0.4ml/min. Proteins were eluted by performing a linear gradient from 95% 
solvent A (0.1% formic acid) to 95% solvent B (Acetonitrile/0.1% formic acid) over 15 
minutes. 
 
Mass spectrometry was performed on an in line Aglient 6530 Q2ToF mass 
spectrometer in electrospray(+ESI) ionization mode (with source settings as follows: 
drying gas temperature 350oC, 11L/min; nebuliser 45 psig; capillary voltage 4000v). 
Data was analysed using Agilent MassHunter Qualitative Analysis B.06.00 software 
with a maximum deconvolutiom algorithm. 
 
 
	
	(			 
Folch homogenates from bovine brain extracts were purchased from Sigma Aldrich. 
Liposomes were by dehydration and rehydration in PBS, sonicated for 5 min and 
passed through 5 freeze2thaw cycles. 3 PM protein and 5 Pl of 1 mg/ml liposome 
solution were incubated for 15 min and directly centrifuged in a TLA2100 (Beckman 
Coulter) for 15’ at 100,000 rpm at 4°C. The supernatant (S) and pellet (P) were 
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immediately separated and analysed using SDS2PAGE and proteins identified with 
Sypro Ruby protein gel stain (Sigma). 
 
 
	#			#)*+&)*+' 
15 µL of a 0.7 mM solution of the desired lipid mixture (12palmitoyl222oleoyl22
glycero232phosphocholine (POPC, 61.9 mol%), 12palmitoyl222oleoyl22glycero232
phospho2L2serine (POPS, 10 mol%), cholesterol (25 mol%), 1,22dioleoyl22glycero2
32phospho2(1'2myo2inositol23'2phosphate) (PI(3)P, 3 mol%), and lissamine2
rhodamine2PE (0.1 mol%), from Avanti Polar Lipids) in chloroform was applied to the 
conductive surface of Indium2Tin Oxide (ITO) coated glass slides (surface resistivity 
8212 X/sq, Sigma2Aldrich Product no. 703192), using a syringe in a meandering 
pattern so as to achieve an even coating of lipids. The resulting lipid deposits were 
briefly dried using a stream of dry N2 gas. Two such slides were applied to a silicon 
rubber gasket with their conductive, lipid coated, sides facing the interior of the 
resulting chamber, approximate volume 500 µL, and held in place with a clip. A 
length of copper tape applied to the gasket provided electrical contact between the 
conductive sides of each slide, but isolated from the interior of the chamber. The 
chamber was then filled with an approximately 600 mM sucrose solution and the 
aperture in the gasket was sealed with a silicon rubber plug. The copper contacts 
were attached to a function generator and an AC voltage of 3 V (peak2to2peak) was 
applied to the chamber, at a frequency of 10 Hz sinusodial and maintained for 2 
hours. The frequency was then reduced to zero incrementally over approximately 10 
minutes, before the solution in the chamber was harvested using a syringe needle. 
 
 
	#			$+	  
82well glass bottom imaging chambers (ibidi GmbH) were prepared by passivation of 
the interior glass surface by incubation overnight in 10 % bovine serum albumin 
(BSA) solution, followed by copious rinsing with MilliQ water. 
 
Tris buffer solutions containing the desired mixtures of proteins and a membrane2
impermeable fluorescent dye (Cascade blue labelled dextran, Mr ~10,000) were 
prepared in Eppendorf tubes to give a final volume of 160 µL, to which was added 40 
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µL of GUV suspension. The resulting 200 µL solution of GUVs and proteins was 
gently mixed by repeated inversion of the tube before being transferred to the 
imaging chambers. After an incubation period of 20 minutes, imaging was conducted 
using a Zeiss LSM 880 laser scanning confocal microscope. A tile scanning 
technique was employed to capture a cross section of a large number of GUVs and 
avoid double counting of fast2moving intraluminal vesicles as can be the case when 
imaging an entire GUV using a z2stack experiment. The pinhole was adjusted to give 
a section depth of 3.1 µm. A manual count was performed of intraluminal vesicles 
with cascade blue fluorescence in their lumen, indicating that they formed after the 
addition of the proteins and contain extravesicular bulk medium. 
 
The total volume of GUV lumens observed was determined using the Fiji image 
analysis software to determine the total GUV lumen volume (total combined lumen 
area, multiplied by the section depth of 3.1 µm) and was then divided by the volume 
of a typical 20 µm diameter GUV (volume of a 20 µm sphere) to give the number of 
“GUV volume equivalents” observed, one volume equivalent being the volume of an 
idealised 20 µm diameter spherical vesicle. The number of ILVs is thus expressed as 
ILVs per GUV volume equivalent. 
 
Additionally, the number of mature ILVs versus nascent ILV buds was assessed by 
counting ILVs that appear to be free2floating in the GUV lumen and those that are 
clearly in contact with, or in close proximity to the ‘parent’ GUV membrane. ‘Free 
floating’ ILVs were counted as those more than 1 µm from the GUV membrane and 
those closer as ‘buds’. Total numbers of free floating ILVs vs buds were then used to 
calculate a percentage for each sample. 
 
 
#,+-
 The modular nature of ESCRT2III components is such 
that it is possible to swap between the proteins’ functional features such as 
membrane binding, and recognition motifs for Vps4 and still end up with active 
ESCRT2III chimeras [38]. We hypothesised that a unique ESCRT2III component 
could be designed by combining the element of membrane recognition by Vps20 
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(Figure 1B), into the oligomerisation potential offered by the Snf7 sequence. The 
ESCRT2III component that seeds the complex, Vps20, is myristoylated at its N2
terminus region providing an additional feature that confers high affinity for 
membrane binding. We therefore swapped the N2terminal hydrophobic helical 
segment of Snf7 [22]  with the Vps20 myristoylation sequence. The residues 
removed provide the natural insertion motif that is being replaced with the lipidation 
to increase stability at the membrane. This sequence is modified by the enzyme N2
myrstoyl transferase to transfer a myristoyl mojety onto the glycine present in the 
sequence. Additionally, we sought to introduce a higher affinity for Vps4 binding. The 
MIM motif of Vps2 was fused at the C2terminus of the Snf7 molecule in order for this 
chimera to bind to the MIT domain of Vps4 (Figure 1C).  This sequence was fused to 
the C2terminal of Snf7 via a flexible linker to provide accessibility to the Vps4 
ATPase. The myristoylation of this designed ESCRT2III should confer more stability 
on the membrane than the wild2type Snf7 has on its own via the N2terminal helix and 
make ESCRT2II function redundant. 
 
 
#,+-		 The covalent attachment of myristic acid to an 
N2terminal glycine residue of a protein is called N2myristoylation. The ESCRT2III 
subunit Vps20 is myristoylated in yeast, a modification that appears to be necessary 
for its localisation and membrane association [39]. An octapeptide grafted in the N2
terminal sequence of Vps20 acts as recognition sequence for the N2
myristoyltransferase NMt1. This enzyme attaches a myristate moiety to the glycine 
contained within the recognition motif MGQKSS [40]. N2myristoylation of proteins in 
 cells is achieved by coexpression of heterologous NMt1 with the target protein 
[41]. Plasmids capable to co2express proteins NMt1 and the Snf72Vps2 protein were 
used to produce the myristoylated chimera. Lipidation of the overexpressed protein 
occurs upon addition of myristic acid and ZnSO4 to the bacterial culture medium as 
previously demonstrated [37]. The non2myristoylated and myristoylated proteins can 
be isolated at high purity and are indistinguishable by molecular weight (Figure 2A), 
with the lipidated form purifying as a monomer and higher oligomeric forms (Figure 
2B). Mass spectrometry of purified protein samples identifies the myristoyl chain 
successfully covalently bonded to the Snf72Vps2 with a molecular weight of 29,809.6 
Da (Figure 2C).  
Page 8 of 23
http://mc.manuscriptcentral.com/rsfs
Under review for Interface Focus
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review
 O
nly
 
 
	
#,+-
	(			 We sought to 
confirm the ability of binding to membranes by the myristoylated chimera using a co2
sedimentation assay with Folch liposomes. Folch homogenates from bovine brain 
extract contain a mixture of lipids including phosphatidyl2inositol and phosphatidyl2
serine, which are both believed to be required for ESCRT2III binding to membranes. 
In the assay, the non2myristoylated chimera is retained in the soluble fraction of the 
centrifugate when not in the presence of Folch liposomes but co2sediments with 
liposomes when these are present (Figure 2D) showing a partial interaction with 
lipids. This result is surprising given that the short N2terminal helical region 
responsible for Snf7 anchoring to membranes was replaced with a myristoylation 
sequence. However, the myristoylation sequence itself is partially hydrophobic, and 
ESCRT2III proteins interaction with membrane is in large part due to electrostatics, 
which may account for the membrane affinity of the unmodified protein. In contrast, 
the myristoylated chimera is present in the sedimented fraction also in the absence 
of liposomes, thus suggesting a propensity to form supramolecular assemblies 
capable to sediment in the conditions of the assay. In the presence of liposomes, the 
myristoylated protein completely partitions in the sedimented fraction thus confirming 
the ability the lipid tail to increase the affinity for phospholipid membranes.  It is clear, 
however, that co2sedimentation assay cannot resolve the difference in affinity 
between the unmodified and myristoylated protein as both show significant binding to 
the membrane fraction. 
 
 
 	
 #,+-  #	 	 ## 
	
		#, The membrane binding 
ability showed by both lipidated and non lipidated Snf72Vps2 chimeras prompted us 
to investigate if these proteins were capable of performing membrane remodelling 
and the extent of the remodelling process. We therefore compared the ability of 
myristoylated and non2myristoylated chimeras to generate ILVs filled with bulk2phase 
within micron2size GUVs. The bulk2phase uptake GUV2based assay has been 
previously used to quantify ESCRT complexes activity [18]. In our assay, 0.1 mol% 
rhodamine labelled PE2lipids (red) were incorporated within electroformed GUVs with 
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a composition of 61.9:10:3:25 POPC:POPS:PI(3)P:cholesterol. Snf7 or Snf72Vps2 
chimeras were added, in separate experiments, to a solution of GUVs of matched 
osmolarity, containing 10 kDa dextran molecules labelled with cascade blue (false 
coloured green in images in Figure 3) and the formation of ILVs filled with cascade 
blue dextran was observed.  
 
Incorporation of bulk2phase solution within internal compartments within a giant 
vesicle implies that: (a) the proteins can invaginate the GUV membrane to generate 
inward budding and, (b) the membrane buds, which contain the extravesicular 
medium, are closed and in some cases severed at the neck. The efficiency of 
membrane remodelling and encapsulation of dextrans was quantified by scoring the 
number of green ILVs in a fixed size volume of solution containing GUVs (see 
methods).  The quantification of ILVs filled with the fluorescent dextran is therefore 
reported as ILVs per GUV volume equivalent. GUVs in a solution of dextrans prior to 
addition of protein (Snf7 or chimeras) did not contain any detectable green ILVs 
(Figure 4A). However, upon addition of 200 nM Snf7, an average of 1.4 ILVs (per 
GUV volume equivalent) containing fluorescent dextrans were generated. In 
comparison, an average of 5 ILVs per GUV volume equivalent were formed by a 
similar concentration of non2myristoylated Snf72Vps2 chimera. Strikingly, 
myristoylation does make a notable difference to ILV generation, doubling the 
number of ILVs, in assays run with two different concentrations of lipidated protein 
versus the non2lipidated chimera (Figure 4A). Interestingly, Snf72Vps2 chimeras 
operate with a higher efficiency of dextran encapsulation, at concentrations that are 
25% lower than the one required for Snf7 to give a similar number of green ILVs (56 
nM vs. 200 nM; Figure 4A). In contrast, Vps20 wild2type or a constitutively activated 
version of this subunit do not induce any ILV formation at 160 nM, a concentration 
similar to the highest tested for the chimeras [18]. 
 
ILVs formed by both Snf7 and the chimeras were typically in the range 122 µm in 
diameter, although smaller and larger individual ILVs can also be observed. We 
aimed to form mixed complexes by combining the chimeras with Snf7 in a 1:9 ratio 
based on the concept that the native filament forming Snf7 might form more active 
complexes when doped with lower chimera compositions. This turned out not to be 
the case (Figure 4B), where Snf7/chimera complexes tended to present less ILV2
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forming activity than the equivalent concentration of pure chimera. However, these 
activities were still much enhanced when compared to Snf7 alone, demonstrating 
that Snf7 and chimeras do form mixed complexes with enhanced activity compared 
to Snf7 only. Despite this, there is no advantage gained in using this more complex 
mixture compared to the simpler, single2component chimera2only system. 
 
We also observed a certain proportion of green ILVs still attached to the membrane 
both in the Snf7 only and in the chimeras GUV population. This motivated us to 
perform an analysis of the proportion of vesicles still attached versus those free2
floating within GUVs, which revealed no apparent difference between the ability of 
the chimeras and Snf7 to perform vesicle scission (Figure 4C). This may indicate a 
thermally2driven stochastic fission probability for nascent ILV buds (~30240% in this 
case) that is dominated by the properties of the membrane rather than the different 
properties of protein assemblies that drive the initial budding process. Note that for 
 ESCRT systems, the ATPase Vps4 is required for efficient neck scission of ILV 
buds. 
	 	
The membrane remodelling action of the ESCRT2III complex is unique in that this is 
the only known protein assembly capable of generating inward budding of the 
membrane, away from the side of the membrane from which the complex binds. 
, this topological process generates new membrane compartments 
encapsulating transmembrane protein cargo within multivesicular bodies. This 
process can be reconstituted 	 using purified protein components, generating 
intraluminal compartments within GUVs that encapsulate constituents from the 
external media. ESCRT2III function requires the concerted action of four core 
subunits in addition to a AAA+ ATPase that is crucial to maintain the complex 
homeostasis. However, here we have shown preliminary data suggesting that cargo 
encapsulation can be efficiently performed  	 on model membranes using a 
single protein, engineered by merging functional motifs from some of the core 
ESCRT2III subunits.  
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This initial design does not appear to be capable of binding to the ATPase VPS4, as 
tested by standard protein pulldown assays (Supp. Figure 1). Using our current 
chimera protein, approximately ~60280% of membrane invaginations do not sever at 
the neck to form full ILVs. This indicates that neck scission can occur with 
acceptable efficiency in a lipid bilayer GUV, likely due to the energy barrier for the 
scission step being thermally accessible with a moderate probability. However, 
based on the inferred  role of Vps4 in the final energy2dependent scission at 
the neck of ESCRT2generated membrane invaginations, a chimera capable of 
binding Vps4 might improve the efficiency of formation of fully mature ILVs 	.  
 
Our current work is an encouraging starting point towards our goal of engineering a 
simple and efficient molecular machinery for on2demand generation of new 
membrane compartments within artificial cells, inspired by the function of native 
ESCRT2III proteins. We have shown that an ESCRT2III chimera protein is more 
efficient at forming ILVs than the core Snf7 subunit of ESCRT2III alone, which forms 
supramolecular spiral assemblies on the membrane. This is suggestive that an 
efficient  	 machinery should be attainable using a very minimal number of 
engineered components, thus making it a viable approach for the wider bottom2up 
synthetic biology community. While our current chimera can generate ILVs, the 
efficiency of neck scission of bud2like invaginations can be improved. This 
encourages further engineering of an ESCRT2III chimera competent to bind the Vps4 
ATPase as an efficient two2component membrane remodelling tool for artificial cell 
systems. 
 

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FIGURE 1 2 (A) The core membrane scission machinery ESCRT2III generates ILVs. 
(I) Membrane bending by ESCRT2II and seeding of ESCRT2III assembly. (II) The 
subunit Vps20 initiates Snf7 polymerization into a spiral filament (rectangle shaded 
blue) and induces membrane budding. Vps24 stops filament elongation and the 
spiral filament drives membrane buckling into an ILV. (III) Neck constriction of the 
budded vesicle occurs via Vps42mediated ESCRT2III polymer shortening. (IV) Full 
ESCRT2III disassembly in preparation for a second round of intraluminal vesicle 
formation. (B) The myristoylated Snf72Vps2 chimera is labelled as ‘chimera (+)’ in all 
figures for clarity (‘chimera (2)’ indicates the absence of myristoylation). Chimera (+) 
should anchor the membrane via a N2terminal myristoyl group, assemble on the 
membranes via the full2length Snf7 domain and have the ability to bind the Vps4 
enzyme. (C) The chimera protein is designed by fusion of the Vps4 binding region of 
Vps2 (MIM type I) to the C2terminus of the filament subunit Snf7, via a flexible linker. 
An N2myristoyl transferase recognition sequence replaces the first eleven residues of 
the Snf7 N2terminus. 
 
FIGURE 2 2 (A) SDS2PAGE showing the purity of chimera (2) and chimera (+) 
proteins. (B) Size exclusion chromatography of chimera (+). The fractions 
corresponding to the indicated peak have been used for GUV assays. (C) Mass 
spectrometry shows the addition of a myristoyl chain to chimera (2) to give chimera 
(+). (D) Co2sedimentation assays of chimera proteins with Folch liposomes. Chimera 
(2) is soluble in the absence of liposomes but sediments with liposomes when 
present. Chimera (+) solubility is reduced by the myristoyl tail but completely 
sediments with liposomes, indicating binding to membranes. 
 
FIGURE 3 2 Representative confocal microscopy images of ILVs observed after the 
addition of chimera (+), chimera (2) or Snf7 at a concentration of 225 nM. Green = 
Cascade Blue labelled Dextran (~10,000 Da), red = lissamine2rhodamine2PE, 
section depth = 3.1 µm, 40x objective. 
 
FIGURE 4 2 Quantitative analysis of ILV formation 2 ILVs observed per typical GUV 
volume (20 µm diameter sphere). (A) Comparison of the extent of ILV formation by 
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with Tukey multiple comparisons test (p<0.05 for the 56.25 nM and 225 nM chimera 
(+) categories when compared to either control or 200 nM Snf7). (B) Pairwise 
comparison of the activity of pure Chimera protein with a mixture of 90 mol% Snf7 + 
10% Chimera protein (p<0.05 for the 22.5 nM + 202 nM Snf7 chimera (+) category 
when compared to 200 nM Snf7). (C) Analysis of the proportion of ILV ‘buds’; those 
observed to be visibly incident on, or within 1 µm of the parent GUV membrane, as a 
percentage of the total ILVs observed. 
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